|
|
Article: Celgene and National Cancer Institute to Collaborate on Colorectal Cancer Trial Using THALOMID(R).
- Article from:
- PR Newswire
- Article date:
- August 5, 1999
CopyrightCOPYRIGHT 1999 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
THALOMID(R) to be Tested as Adjuvant Agent Following Surgery for
Colorectal Cancer
WARREN, N.J., Aug. 5 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG) today announced the initiation of a randomized, placebo controlled, phase II trial by the intramural Division of Clinical Sciences at the National Cancer Institute (NCI) to administer THALOMID(R) (thalidomide) or placebo to 94 patients following surgical resection of metastases from colon and rectal carcinoma. The THALOMID study group will be treated for 24 months to determine if thalidomide improves disease-free survival rates. Colorectal cancer is the second leading cause of cancer death in the U.S. ...